Cardiovascular effects of cholinesterase inhibitors in Alzheimer's disease;Effets cardio-vasculaires des inhibiteurs de la cholinestérase dans la maladie d'Alzheimer

Revue Neurologique

Volumn 163, Issue 10, 2007, Pages 968-974

  Ferreri, F ^a,b   Agbokou, C ^c   Gauthier, S ^a  

^a MCGILL UNIVERSITY   (Canada)

^b HÔPITAL SAINT ANTOINE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Alzheimer's disease; Autonomic nervous system; Bradycardia; Cholinesterase inhibitors; Syncope

Indexed keywords

AMIODARONE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CIMETIDINE; CLARITHROMYCIN; DILTIAZEM; DONEPEZIL; DOXYCYCLINE; FLECAINIDE; FLUCONAZOLE; FLUOXETINE; GALANTAMINE; GLYCYRRHIZA EXTRACT; KETOCONAZOLE; MEPROBAMATE; METOCLOPRAMIDE; METOPROLOL; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PROPAFENONE; QUINIDINE; RIFAMPICIN; RIVASTIGMINE; TOPIRAMATE; VALPROIC ACID; VERAPAMIL;

ABDOMINAL DISEASE; ALZHEIMER DISEASE; ANOREXIA; ASTHENIA; BRADYCARDIA; CARDIOVASCULAR EFFECT; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; HEART ARRHYTHMIA; HEART SINOATRIAL BLOCK; HUMAN; INSOMNIA; MUSCLE CRAMP; NAUSEA; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; REVIEW; SOMNOLENCE; SYNCOPE; VERTIGO; VOMITING;

EID: 36248968813     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(07)92641-7     Document Type: Article

References (26)

1. BENTUE-FERRER D, TRIBUT O, POLARD E, ALLAIN H. (2003). Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs, 17:947-63.
2. BIRKS J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev, CD005593.
3. BORDIER P, GARRIGUE S, LANUSSE S, et al. (2006). Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease. CNS Drugs, 20:411-7.
4. BORDIER P, LANUSSE S, GARRIGUE S, et al. (2005). Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging, 22:687-94.
5. BREMBILLA-PERROT B, REGENT MC, HANESSE B, et al. (2004). Troubles de la conduction auriculoventriculaire paroxystiques lies a la prise d'un anticholinesterasique. Arch Mal Coeur Vaiss, 97:1265-7.
6. Crismon ML. (1998). Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease. Pharmacotherapy, 18:47-54.
7. DAVOUS P, DELACOURTE A. (1999). Maladie d'Alzheimer. Encycl Méd Chir (Elsevier, Paris), Neurologie 17-056-A-10, 15p.
8. DUNN NR, PEARCE GL, SHAKIR SA. (2000). Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol, 14:406-8.
9. FERRERI F, AGBOKOU C, GAUTHIER S. (2006). Cognitive Dysfunctions in Schizophrenia: Potential Benefits of Cholinesterase Inhibitor Adjunctive Therapy. J Psychiatry Neurosci, 31:369-76.
10. FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12:189-98.
11. GAUTHIER S. (2001). Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging, 18:853-62.
12. GAUTHIER S. (2002). Advances in the pharmacotherapy of Alzheimer's disease. CMAJ, 166:616-23.
13. GAUTHIER S. (2006). Managing discontinuation syndrome in patients with dementia. J Psychiatry Neurosci, 31:72.
14. GAUTHIER S, REISBERG B, ZAUDIG M, et al. (2006). Mild cognitive impairment. Lancet, 367:1262-70.
15. GREENBERG SM, TENNIS MK, BROWN LB, et al. (2000). Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol, 57:94-9.
16. HELMER C, PERES K, LETENNEUR L, et al. (2006). Dementia in Subjects Aged 75 Years or Over within the PAQUID Cohort: Prevalence and Burden by Severity. Dement Geriatr Cogn Disord, 22:87-94.
17. IMAIZUMI S, MAZGALEV T, DREIFUS LS, et al. (1990). Morphological and electrophysiological correlates of atrioventricular nodal response to increased vagal activity. Circulation, 82:951-64.
18. LEENTJENS AF, KRAGTEN JA. (2006). [Complete atrioventricular block during galantamine therapy]. Ned Tijdschr Geneeskd, 150:563-6.
19. MASUDA Y. (2004). Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease-from basic research to bedside. Curr Alzheimer Res, 1:315-21.
20. MCLAREN AT, ALLEN J, MURRAY A, BALLARD CG, KENNY RA. (2003). Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord, 15:183-8.
21. MORGANROTH J, GRAHAM S, HARTMAN R, ANAND R. (2002). Electrocardiographic effects of rivastigmine. J Clin Pharmacol, 42:558-68.
22. PAKRASI S, MUKAETOVA-LADINSKA EB, MCKEITH IG, O'BRIEN JT. (2003). Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry, 18:879-86.
23. PEARSON VE. (2001). Galantamine: a new alzheimer drug with a past life. Ann Pharmacother, 35:1406-13.
24. SERRATRICE G, VERSCHUEREN A. (2005). Système nerveux autonome. Encycl Méd Chir (Elsevier, Paris), Neurologie 17-003-J-10, 18p.
25. th International Conference on Alzheimer's disease and related disorders, Madrid, July 15-20.
26. WORLD HEALTH ORGANIZATION. (2004). Cholinesterase inhibitors and cardiac arrhythmias. WHO Drug Information - Safety and efficacy issues, 18: 273-4.